| Literature DB >> 30098136 |
Kai Zhang1, Linru Zhao1, Zuowang Ma1, Weiding Wang1, Xiongfeng Li1, Yue Zhang1, Meng Yuan1, Xue Liang1, Guangping Li1.
Abstract
BACKGROUND Atrial remodeling especially in the form of fibrosis is the most important substrate of atrial fibrillation (AF). The aim of this study was to investigate the effects of doxycycline on chronic intermittent hypoxia (CIH)-induced atrial remodeling and the pathophysiological mechanisms underlying such changes. MATERIAL AND METHODS A total of 30 Sprague-Dawley rats were randomized into 3 groups: Control group, CIH group, and CIH with doxycycline treatment group. CIH rats were subjected to CIH 6 h/d for 30 days and treatment rats were administrated doxycycline while they received CIH. After the echocardiography examination, rats were sacrificed at 31 days. The tissues of atria were collected for histological and molecular biological experiments, Masson staining was used to evaluate the extent of atrial fibrosis, microRNA-21, and its downstream target phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K) were assessed. RESULTS Compared to the control group, the CIH rats showed higher atrial interstitial collagen fraction, increased microRNA-21, PI3K levels, and decreased PTEN levels. Doxycycline treatment attenuated CIH-induced atrial fibrosis, reduced microRNA-21 and PI3K, and increased PTEN. CONCLUSIONS CIH induced significant atrial remodeling, which was attenuated by doxycycline in our rat model. These changes may be explained due to alterations in the microRNA-21-related signaling pathways by doxycycline.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30098136 PMCID: PMC6100459 DOI: 10.12659/MSM.909800
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Primers used for real-time PCR.
| Gene | Primers | Temperature (°C) |
|---|---|---|
| miRNA-21 stem-loop primer | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACATTTGG | 75.04 |
| miRNA-21 forward primer | GCCGAGCTGGTAAAATGGAA | 56.00 |
| Universal reverse primer | GTATCCAGTGCAGGGTCCGAGGT | 63.77 |
| U6 | FP: CTCGCTTCGGCAGCACA | 56 |
| RP: AACGCTTCACGAATTTGCGT | ||
| GAPDH | FP: GGCACAGTCAAGGCTGAGAATG | 56 |
| RP: ATGGTGGTGAAGACGCCAGTA | ||
| PTEN | FP: ACTGCAGAGTTGCACAGTATC | 56 |
| RP: GTCCGTCCTTTCCCAGCTTTA |
F – forward; R – reverse.
Weight parameters and echocardiography parameters.
| Parameter | Control (n=10) | CIH (n=10) | Treatment (n=10) | P value |
|---|---|---|---|---|
| Body weight (g) | 432.4±12.60 | 425±5.46 | 405.6±20.49 | 0.001 |
| Heart weight (g) | 1.24±0.07 | 1.48±0.07 | 1.30±0.13 | <0.001 |
| LAD (mm) | 4.02±0.56 | 3.89±0.44 | 3.68±0.46 | 0.299 |
| LVEDD (mm) | 7.03±0.55 | 6.64±0.70 | 6.44±0.46 | 0.085 |
| LVESD (mm) | 4.63±0.44 | 4.55±0.65 | 4.18±0.54 | 0.167 |
| PAT (ms) | 38.40±2.16 | 26.86±5.22 | 26.16±6.17 | |
| LVEF (%) | 64±3.76 | 60.24±8.73 | 65.28±9.03 | 0.309 |
| mPAP (mmHg) | 52.72±0.97 | 57.91±2.35 | 58.23±2.78 | <0.001 |
LAD – left atrial diameter; LVEDD – left ventricular end diastolic dimension; LVESD – left ventricular end systolic dimension; PAT – pulmonary artery acceleration time; mPAP – mean pulmonary artery pressure; LVEF – left ventricular ejection fraction.
The atrial collagen fraction in the three groups.
| Fields | Control (n=5) | CIH (n=5) | Treatment (n=5) |
|---|---|---|---|
| LA (400×) | 0.0150±0.0023 | 0.0640±0.0084 | 0.0284±0.0069 |
| RA (400×) | 0.0158±0.0022 | 0.0738±0.0102 | 0.0324±0.0058 |
| LA (200×) | 0.0133±0.0027 | 0.0485±0.0106 | 0.0207±0.0068 |
| RA (200×) | 0.0202±0.0038 | 0.0613±0.0065 | 0.0308±0.0063 |
LA – left atria; RA – right atria.
Figure 1Comparison of collagen fraction between 3 groups (n=5). (A) High-power fields of left atria (×400); (B) High power fields of right atria (×400); (C) Middle power fields of left atria (×200); (D) Middle power fields of right atria (×200). * Significant difference between the control and CIH groups, ** P<0.01, *** P<0.001. # Significant difference between CIH and treatment groups, ## P<0.01. NS – not significant.
Figure 2Photomicrographs of Masson staining (n=5). (A) Control group; (B) CIH group; (C) Treatment group.
Figure 3mRNA levels of microRNA-21 and PTEN determined by RT-qPCR (n=5). (A) Comparison of microRNA-21 in left atria; (B) Comparison of microRNA-21 in right atria; (C) Comparison of PTEN in left atria; (D) Comparison of PTEN in right atria. * Significant difference between the control and CIH groups. # Significant difference between CIH and treatment groups. NS – not significant.
Figure 4Photomicrographs of Immunohistochemistry staining (n=5). Protein levels of PTEN and PI3K determined by immunohistochemistry staining showed that protein levels of PTEN in the CIH group (B) were lower than in the control group (A), and protein levels of PTEN in the treatment group (C) fell between these values. Protein levels of PI3K in the CIH group (E) were higher than in the control group (D), whereas protein levels of PI3K in the treatment group (F) were lower.
Figure 5Protein levels of PTEN and PI3K determined by Western blot (n=5). (A) Comparison of PTEN in left atria; (B) Comparison of PTEN in right atria; (C) Comparison of PI3K in left atria; (D) Comparison of PI3K in right atria. * Significant difference between the control and CIH groups, ** P<0.01. # Significant difference between CIH and treatment groups, ## P<0.01. NS – not significant.